RBR-5m6748进行中（未招募）未知
Validation of the use of galectin-3 as a biomarker for determining prognosis of patients with Chagas disease.
Hospital São Rafael0 个研究点开始时间: 2015年4月14日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18Y 至 70Y（—）
入选标准
- •Chagas disease confirmed by 2 different serological tests; optimized drug therapy; NYHA functional class II-III-IV or patients with the indeterminate form; patients of any gender and aged 18 to 70 years.
排除标准
- •Valvulopathy with hemodynamic consequences; chronic use of immunosuppressive agents; renal failure on current treatment by dialysis; acute infections or systemic infections in accordance with the definition of sepsis ACCP/SCCM (American College of Chest Phisicians/Society of Critical Care Medicine); abuse alcohol or illicit drugs (Based on DSM IV), any comorbidity with impact on survival in two years; liver, pulmonary, hematologic, neoplastic, bone, inflammatory or infectious diseases.
研究者
相似试验
已完成
不适用
Evaluation of Galectin-3 expression as a prognostic factor in non-small cell lung cancer patientson-small cell lung cancerJPRN-UMIN000026869Shiga University of Medical Science250
已完成
不适用
Galectin-3 as a Biomarker in Patients With Chagas DiseaseChagas DiseaseNCT01842854Hospital Sao Rafael60
尚未招募
不适用
Galectin-3 and oral submucous fibrosisCTRI/2020/12/029928Dr Hetvi Sheth
已完成
不适用
Galectin-3 Binding Protein in Cardiovascular Disease and Chronic Heart FailureCardiomyopathiesHeart FailureCoronary Artery DiseaseNCT01210157Heidelberg University373
已完成
不适用
"Galectin-3 as a Marker of Subclinical Inflammation in FMF"Ailesel Akdeniz AteşiNCT06451471Turkish League Against Rheumatism154